Val­neva's chikun­gun­ya vac­cine on track for FDA nod af­ter long-term an­ti­body da­ta

The chikun­gun­ya virus met its match in Val­ne­va’s vac­cine can­di­date, VLA1553, ac­cord­ing to da­ta from an an­ti­body per­sis­tence tri­al re­leased to­day.

The tri­al found that 99% of 363 par­tic­i­pants re­tained neu­tral­iz­ing an­ti­bod­ies 12 months af­ter a sin­gle dose of vac­cine in the com­pa­ny’s ear­li­er, larg­er Phase III tri­al, called VLA1553-301. The par­tic­i­pants from the long-term study will con­tin­ue to be mon­i­tored for at least five years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER